Although the therapeutic effects of type I IFN monotherapy (IFN-α, pegylated IFN-α, IFN-β, etc.)are limited for the treatment of advanced melanoma [4], many protocol regimens that contain Type I IFN have been investigated [1,2,17,18]. The gene discussed is IFNA2; the disease is melanoma.